Patent and Trademark Office extends protection of Clearmind’s proprietary MEAI and expands its potential market Tel Aviv, Israel / Vancouver, Canada, Dec. 21, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under…

Source

Previous articleNuminus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022
Next articlePsychedelics Weekly – Prop 122 and Data Privacy, Ending the Crack/Cocaine Sentencing Disparity, and the High Cost of Psychedelic Therapy